文献速递肺外科

肺癌肺叶切除术的费用:STS与Medicare数据联合分析

Costs Associated With Lobectomy for Lung Cancer: An Analysis Merging STS and Medicare Data.
PubMed 文献 · Ann Thorac Surg · 2020-11-12

该研究联合STS通用胸外科数据库与Medicare数据,分析2008—2013年临床I期肺癌肺叶切除术的90天费用。结果显示平均90天费用为45,080±38,239美元,费用变异受患者人口学与临床因素、医院特征及并发症发生与严重程度驱动。发生1个及以上并发症平均增加费用27,259美元。

要点

  • 临床I期肺癌肺叶切除术平均90天费用为45,080±38,239美元。
  • 高龄、ASA III/IV级、FEV1<80%预计值、BMI异常、吸烟史、脑血管病、慢性肾病、功能状态受损、开胸、手术时间延长、政府医院、大城市及地理区域与费用增加相关。
  • 发生1个及以上术后并发症平均增加费用27,259美元,费用随并发症数量增加。

核心结论

  • 肺叶切除术的90天诊疗费用存在显著变异,变异由患者人口学与临床因素、医院特征以及并发症的发生与严重程度驱动。

研究设计与样本

  • 回顾性队列分析,查询STS通用胸外科数据库2008—2013年临床I期肺癌肺叶切除术患者,分析成功链接Medicare数据的患者,医院费用由收费经成本收费比估算。

主要发现

  • 肺叶切除术平均90天费用为45,080±38,239美元。
  • 与显著增加费用相关的变量包括年龄≥75岁、ASA III或IV级、FEV1<80%预计值、BMI<18.5或>35、当前或既往吸烟、脑血管病、慢性肾病、功能状态受损、开胸手术、手术时间延长、政府医院、大城市环境及地理位置。
  • 发生1个及以上术后并发症总体平均增加费用27,259美元。
  • 增加费用随并发症数量增加;孤立性喉返神经麻痹增加3,911美元,呼吸衰竭增加35,011美元,分别为最低和最高增加费用。

临床怎么用

  • 临床评估肺癌肺叶切除术费用风险时,应综合考虑患者年龄、ASA分级、肺功能、BMI、合并症、功能状态、手术方式、手术时间及医院特征。
  • 围手术期应重视并发症预防,尤其呼吸衰竭等严重并发症,因其与显著增加的费用相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Costs related to care of patients who undergo lobectomy for lung cancer may vary depending on patient, disease, and treating facility characteristics. We aimed to identify underlying case mix factors that contribute to variability of 90-day costs of lobectomy for early-stage lung cancer. METHODS: The Society of Thoracic Surgeons General Thoracic Surgery Database was queried for lobectomy for clinical stage I lung cancer (2008-2013). Demographics, clinical outcomes, and 90-day episode-of-care costs across all care settings were analyzed for patients successfully linked to Medicare data. Hospital costs were estimated from charges using cost-to-charge ratios. Comprehensive regression models were created to identify impact of preoperative patient factors and hospital characteristics on costs, and to delineate additive costs due to perioperative outcomes and complications. RESULTS: The mean 90-day cost for lobectomy was $45,080 ± $38,239. Variables associated with significant additive costs were age greater than or equal to 75 years, American Society of Anesthesiologists classification III or IV, forced expiratory volume in 1 second less than 80% predicted, body mass index less than 18.5 or greater than 35, current or past smoker, cerebrovascular disease, chronic kidney disease, impaired functional status, open thoracotomy, prolonged operative time, government hospitals, metropolitan setting, and geographic location. Patients with 1 or more postoperative complication resulted in an overall mean added cost of $27,259. Added costs increased with the number of complications; isolated recurrent laryngeal nerve paresis ($3,911) and respiratory failure ($35,011) were associated with the least and most additive cost, respectively. CONCLUSIONS: Lobectomy is associated with substantial variability of episode-of-care costs. Variability is driven by patient demographic and clinical factors, hospital characteristics, and the occurrence and severity of complications.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Medbery RL, Fernandez FG, Kosinski AS, et al. Costs Associated With Lobectomy for Lung Cancer: An Analysis Merging STS and Medicare Data. Ann Thorac Surg. 2020. PMID: 33188754. doi:10.1016/j.athoracsur.2020.08.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。